Global pharmaceutical leader Lupin has enhanced its flagship Humrahi program, adding robust heart health support to its proven diabetes care framework. The revamped program was unveiled at the Research Society for the Study of Diabetes in India (RSSDI) conference in New Delhi, marking a significant step toward holistic patient care.

As diabetes and cardiovascular diseases emerge as major global health concerns, Humrahi offers a dual approach that integrates diabetes management with strategies for maintaining heart health. Patients will benefit from tailored insights into heart-friendly practices, regular monitoring, and expert guidance to manage cardiovascular risks often linked with diabetes.

Rajeev Sibal, President – India Region Formulations, Lupin, highlighted the program’s impact:
"Humrahi is designed to address non-adherence to therapy—a critical challenge in healthcare. Through personalized support and awareness initiatives, we aim to improve patient outcomes and bridge gaps in chronic disease management."

Cricket legend and brand ambassador Kapil Dev praised the initiative, saying, "Humrahi is like a trusted teammate, consistently supporting patients in managing their health."

Dr. B M Makkar, Organising Chairman of RSSDI, emphasized, "Humrahi empowers patients to actively manage their health journey with ease."

Dr. Banshi Saboo, Chair-Elect of the International Diabetes Federation (Southeast Asia), lauded the program’s focus on education and personalized care: "This initiative addresses non-communicable diseases with a much-needed, patient-centric approach."

Lupin’s Humrahi program continues to set new benchmarks by providing a comprehensive, patient-friendly platform that bridges the gap between effective treatment and long-term health outcomes.